The latest announcement is out from Avidity Biosciences (RNA).
Avidity Biosciences has unveiled promising initial results from the EXPLORE44™ trial for its drug delpacibart zotadirsen, aimed at treating Duchenne muscular dystrophy mutations amenable to exon 44 skipping. The findings show encouraging signs of increased exon skipping, boosted dystrophin production, decreased creatine kinase levels, and a favorable safety profile in patients. With the full enrollment of the EXPLORE44 trial, Avidity is now progressing to additional studies and regulatory engagement to fast-track the development of this potential DMD therapy.
See more data about RNA stock on TipRanks’ Stock Analysis page.
